In this study, we not only demonstrated the effective inhibition of ovarian cancer expansion by the novel ERβ agonist OSU-ERb-12 but also showed that the activation of ERβ by OSU-ERb-12 is able to deplete CSCs in ovarian cancer. Here, ESR2 is linked to ovarian carcinoma.